1Yang E, Ahes T, Anupindi SA. Early Mycoplasma pneumoniaeinfection presenting as multiple pulmonary masses: an unusual presentation in a child [ J ]. Pediatr Radiol, 2008, 38 (4) : 477- 480.
2Youn YS, Lee KY, Hwang JY, et ah Difference of clinical features in childhood Mycoplasma pneumoniae pneumonia [ J ]- BMC Pediatr, 2010, 6(10) : 48.
3Waites KB, Talkington DF. Mycoplasma pneumoniae and its role as a human pathogen [J]. Clin Mierobiol Rev, 2004, 17(4) : 697-728.
4Morozumi M, Iwata S, Hasegawa K, et al. Increased maerolide resistance of Myeoplasma pneumoniae in pediatric patients with community-acquired pneumonia [ J ]. Antimicrob Agents Chemother, 2008, 52( 1 ): 348-350.
5Suzuki S, Yamazaki T, Narita M, et al. Clinical evaluation of macrolide-resistant Myeoplasma pneumoniae [ J ]. Antimierob Agents Chemother, 2006, 50(2): 709-712.
6Xin DL, Mi ZH, Han X, et al. Molecular mechanisms of macrolide resistance in clinical isolates of Myeoplasma pneumoniae from China [ J ]. Antimicrob Agents Chemother, 2009, 53(5) : 2158-2159.
7Liu Y, Ye XY, Zhang H, et al. Antimicrobial susceptibility of Mycoplasma pneumoniae isolates and molecular analysis of macrolide-resistant strains from Shanghai, China [ J ]. Antimicrob Agents Chemother, 2009, 53(5) : 2160-2162.
8Peuchant O, Menard A, Renaudin H, et al. Increased macrolide resistance of Mycoplasma pneumoniae in France directly detected in clinical specimens by real-time PCR and melting curve analysis [J]. J Antimicrob Chemother, 2009, 64(1): 52-58.
9Wolff BJ, Thacker WL, Schwartz SB, et ah Detection of macrolide resistance in Mycoplasma pneumoniae by real-time PCR and high-resolution meh analysis [ J ]. Antimicrob Agents Chemother, 2008, 52(10) : 3542-3549.
10Miyashita N, Maruyama T, Kobayashi T, et al. Community- acquired macrolide-resistant Mycoplasma pneumoniae pneumonia in patients more than 18 years of age [ J ]. J Infect Chemother, 2011, 17(1): 114-118.
4Yang E, Altes T, Anupindi SA. Early Mycoplasma pneumoniae infection presenting as multiple pulmonary masses: an unusual presentation in a child [J]. Pediatr Radiol,2008,38 (4):477- 480.
5Gaillat J, Elahauh A, deBarbeyrae B, et al. Community epidemiology of Chlamydia and Myeoplasma pneumoniae in LRTI in France over 29 months [J]. Eur J Epidemiol,2005,20 (7) :643-651.
6Nagalingam NA, Adesiyun AA, Swanston WH, et al. Prevalence of Mycoplasma pneumoniae and Chlamydia pneumoniae in pneumonia patients in four major hospitals in Trinidad [J]. New Microbiol, 2004,27 (4) : 345 -351.
7Tamura A, Matsubara K, Tanaka T, et all. Methylprednisolone pulse therapy for refractory Mycoplasrna pneumoniae pneumonia in children [J]. J Infect,2008,57(3):223-228.
8Morozumi M, Iwata S, Hasegawa K, et al. Increased macrolide resistance of Mycoplasma pneumoniae in pediatric patients with community-acquired pneumonia [J]. Antimierob Agents Chemother, 2008,52 ( 1 ) : 348-350.
9Pereyre S, Charron A, Renaudin H, et al. First report of macrolideresistant strains and description of a novel nucleotide sequence variation in the P1 adhesin gene in Mycoplasma pneumoniae clinical strains isolated in France over 12 years [J]. J Clin Microbiol ,2007,45 ( 11 ) : 3534-3539.
10Bebear CM, Pereyre S. Mechanisms of drug resistance in Mycoplasma pneumoniae [J]. Curr Drug Targets Infect Disord, 2005,5(3) :263-271.
3Tao KM, Yang LQ, Liu YT, et al. Volatile anesthetics might be more beneficial than propofol for postoperative liver function in cirrhotic patients receiving hepatectomy [ J ]. Med Hypotheses, 2010, 75(6) : 555-557.
4Sharma P, Singh S, Sharma BC, et al. Propofol sedation during endoscopy in patients with cirrhosis, and utility of psychometric tests and critical flicker frequency in assessment of recovery from sedation [J]. Endoscopy, 2011, 43(5) : 400-405.
5Thomas P. Atkinson. Clinical Presentation and Laboratory Find- ings of blycoplasmapneumoniae Respiratory Infectionsin Children [ J]. Current Pediatric Reviews ,2013.9.4.
